Capricor Therapeutics, Inc. revenue

Revenue history

AnnualQuarterly

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Capricor Therapeutics, Inc.: revenue history, annual

Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	1	0	1	5	6	4	3	2	1	0	0	3	25	22	0
Growth on the year before	—	−85.6%	+157.4%	+851.2%	+15.3%	−27.5%	−33.3%	−37.3%	−39.9%	−69.1%	−21.1%	+941.8%	+886.8%	−11.5%	−100.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Capricor Therapeutics, Inc.	$22.3m	-11.5%	260.7%
Janux Therapeutics, Inc.	$24.0m	5367.0%	45.7%
Crispr Therapeutics AG	$25.2m	-34.3%	-47.1%
Abeona Therapeutics Inc.	$25.5m	-87.7%	212.0%
Scynexis Inc	$19.2m	489.8%	-47.9%
Celularity Inc	$18.7m	-58.1%	7.2%

Compare with peers

• Janux Therapeutics, Inc. revenue
• Crispr Therapeutics AG revenue
• Abeona Therapeutics Inc. revenue
• Scynexis Inc revenue
• Celularity Inc revenue

Head to head: CAPR vs JANXCAPR vs CRSPABEO vs CAPR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Capricor Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Capricor Therapeutics, Inc.